Pharmacotherapies for Obesity: Past, Current, and Future Therapies

Table 6

Recent randomised controlled trials of weight loss therapies with 2-years followup.

Drug	No subjects	Outcomes				Serious adverse events	Reference
		Absolute weight loss (kg) (95% CI)	≥5% weight loss	≥10% weight loss	Change in WC (cm)
Lorcaserin	P-684	3.0%±0.2%	50.3%	7.7%	4.3±0.2	NS	[120]
	L-564	7.0%±0.2%	67.9%	22.6%	8.1±0.2
		𝑃<.001	𝑃<.001	𝑃<.001	𝑃<.001
Taranabant	P-244	1.4 (0.3, 2.5)	30.3%	13.4	−2.7 (1.5, 3.8)	NS	[23]
	TB 2 mg-264	6.4 (5.3, 7.4),; 𝑃<.001	59.6, 𝑃<.001	33, 𝑃<.001	−6.3 (5.2, 7.4) 𝑃<.05
	TB 4 mg-260	7.6 (6.5, 8.7),; 𝑃<.001	64.8, 𝑃<.001	37.9, 𝑃<.001	−7.0 (5.9, 8.1), 𝑃<.01

Absolute weight loss = weight loss from baseline; WC: waist circumference, NR: not recorded, TB: taranabant, NS: not significant; P: placebo; L: lorcaserin.